寡转移性结直肠癌的预后、局部治疗作用及一线化疗影响:TRIBE与TRIBE2研究汇总分析
该汇总分析基于III期TRIBE和TRIBE2研究,按ESMO定义将1187例mCRC患者分为OMD(28%)与非OMD(72%)。OMD与更长的PFS(14.0 vs 10.1个月)和OS(38.2 vs 22.0个月)相关。FOLFOXIRI/bev对比双药/bev的获益不受OMD及肿瘤负荷影响,OMD患者更常接受局部治疗。
要点
- OMD是mCRC的阳性预后因素,PFS和OS均显著延长。
- 一线FOLFOXIRI/bev强化获益与转移范围及肿瘤负荷无关。
- OMD患者应高度考虑局部治疗,尤其一线及后续精选病例。
核心结论
- OMD是mCRC的阳性预后因素。
- 一线治疗强化获益不依赖于转移播散范围和肿瘤负荷。
- OMD患者应高度考虑局部治疗。
研究设计与样本
- III期TRIBE和TRIBE2研究的汇总分析。
- 比较FOLFOXIRI/bev与双药(FOLFOX或FOLFIRI)/bev。
- 按ESMO定义将患者分为OMD与非OMD。
- 1187例入组,1096例可分类:OMD 312例(28%),非OMD 784例(72%)。
- OMD中低肿瘤负荷者126例(40%)。
主要发现
- OMD组PFS为14.0个月,非OMD组为10.1个月(p<0.01)。
- OMD组OS为38.2个月,非OMD组为22.0个月(p<0.01)。
- 多变量模型证实上述结果。
- FOLFOXIRI/bev对比双药/bev的获益在OMD和肿瘤负荷亚组间无差异(交互作用p>0.05)。
- OMD患者更常接受局部治疗(p<0.01),OMD/低肿瘤负荷者首次进展后接受局部治疗机会更高(p<0.01)。
关键数值与推荐
- OMD定义依据ESMO标准。
- OMD组PFS 14.0个月 vs 非OMD组10.1个月(p<0.01)。
- OMD组OS 38.2个月 vs 非OMD组22.0个月(p<0.01)。
- 治疗强化与OMD/肿瘤负荷交互作用p>0.05。
临床怎么用
- 对mCRC患者应评估是否为OMD以进行预后分层。
- OMD患者一线可考虑FOLFOXIRI/bev强化治疗,获益不受转移范围影响。
- OMD患者应积极考虑局部治疗,包括一线及后续精选病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oligometastatic disease (OMD) identifies tumours with limited metastatic spread. OMD definition is not univocal and no data from clinical trials are available about the prognostic effect of OMD in metastatic colorectal cancer (mCRC), the impact of locoregional treatments (LRTs) and the effect of chemotherapy intensification in these patients. The role of tumour burden (TB) in driving therapeutic choices is also debated. PATIENTS AND METHODS: We performed a pooled analysis of phase III TRIBE and TRIBE2 studies comparing FOLFOXIRI/bevacizumab (bev) to doublets (FOLFOX or FOLFIRI)/bev. Patients were grouped in OMD versus non-OMD based on the European Society for Medical Oncology definition. Among patients with OMD, those with OMD/low TB were compared with all the others. RESULTS: Of 1187 patients enrolled, 1096 were classified as OMD (N = 312 [28%]) or non-OMD (N = 784 [72%]). Among patients with OMD, 126 (40%) were OMD/low TB. OMD was associated with longer progression-free survival (14.0 versus 10.1 months; p < 0.01) and overall survival (38.2 versus 22.0 months; p < 0.01). These results were confirmed in multivariable models. The benefit provided by FOLFOXIRI/bev compared with doublets/bev did not differ in accordance with OMD and TB (p for interaction >0.05). Patients with OMD underwent LRTs more frequently (p < 0.01) and those with OMD/low TB had higher chance to undergo LRTs after the first progression (p < 0.01). CONCLUSIONS: OMD is a positive prognostic factor in mCRC. The benefit from the upfront treatment intensification is independent of the metastatic spread extent and TB. LRTs should be highly considered in these patients, mainly during the first-line therapy but also at later stages of treatment history in selected cases.
引用
- Moretto R, Rossini D, Zucchelli G, et al. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer. 2020. PMID: 32979645. doi:10.1016/j.ejca.2020.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。